Pfizer meets amyloidosis rival

BridgeBio Wins FDA Approval for ATTR-CM Drug, Launching Competition with Pfizer
BridgeBio secured approval for Attruby Friday, along with the all-important mortality benefit that could give the drug a significant boost in the market against Pfizer’s tafamidis and potentially Alnylam’s Amvuttra.
Pfizer meets amyloidosis rival as BridgeBio wins FDA nod for Attruby
BridgeBio Pharma (BBIO) wins FDA nod Attruby for rare heart disorder, ATTR-CM challenging Pfizer's (PFE) Vyndaqel. Read more here.
BridgeBio Pharma : FDA Approves Heart Disease Drug 'acoramidis'
BridgeBio Pharma Inc. (BBIO) announced that the U.S. Food and Drug Administration approved Attruby or acoramidis, an
BridgeBio Gets US Approval for Heart Drug to Compete with Pfizer
BridgeBio Pharma Inc. gained US approval for a drug to treat a progressive and deadly form of heart disease, paving the way for the biotech company to go head-to-head with Pfizer Inc. in an increasingly competitive market.
US FDA approves BridgeBio's drug for rare heart condition
The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said on Friday, making it the first new treatment in a market dominated by Pfizer's blockbuster Vyndaqel.
BridgeBio announces FDA approved Attruby for ATTR-CM patients
Pharma announced that the U.S. Food and Drug Administration approved Attruby, an orally-administered near-complete stabilizer of
BridgeBio wins FDA approval for heart disease drug
The drug, known scientifically as acoramidis, will be sold by BridgeBio under the brand name Attruby. The FDA cleared Attruby to treat patients with the heart condition known as transthyretin amyloid cardiomyopathy,
pharmaphorum4d
Pfizer, BioNTech submit to FDA for Covid vaccine in under 5s
Pfizer and BioNTech have announced that they have submitted an Emergency Use Authorisation (EUA) to the US Food and Drug Administration (FDA ... or approved monovalent COVID-19 vaccine.
Tennessean25d
Moderna, Pfizer or Novavax? How the three Covid-19 vaccines differ according to Yale Medicine
It was later granted full FDA approval in August 2021 for people ages 16 and older. Pfizer’s and Moderna's vaccine has been updated over time to target currently circulating variants ...
Trump nominates Marty Makary, who opposed COVID vaccine mandates, to head FDA
President-elect Donald Trump has nominated a critic of COVID-19 health measures to lead the Food and Drug Administration.
pharmaphorum14d
After FDA nod, Pfizer joins GSK in RSV vaccine market
The FDA has approved Pfizer’s respiratory syncytial virus (RSV) vaccine for older adults, just a few weeks after a rival shot from GSK became the first to be cleared in the US. Pfizer’s ...
Reuters3d
Approvals News | Today's Latest Stories | Reuters
US FDA declines full approval for Intercept's liver ... 2024 The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract ...
justthenews2d
Operation Warp Speed official questions COVID vaccine purity, worries 'they may ingrate' into DNA
Robert Redfield says he's "proud" of work on President Trump's initiative but believes COVID vaccines should be "critically ...
biopharma-reporter12d
FDA removes clinical hold on Novavax’s COVID-19-influenza combo vaccine
The FDA had put a clinical hold on Novavax’s COVID-19-influenza combo vaccine after an adverse event in a patient. The ...
FierceBiotech26d
Pfizer, amid Abyrsvo launch, lets its RSV pipeline dry up in crowded space
Pfizer’s respiratory syncytial virus (RSV) pipeline appears to have run dry of candidates following the cessation of work on both an oral medicine and an RSV-flu combo vaccine in quick succession.